Science & Medicine

Last year, the FDA declared Ozempic and Wegovy in shortage, a designation that allows specialized pharmacies to mix up their own, cheaper versions of the weight loss drugs, putting these medications into the hands of patients who often don’t know their original source and pedigree.

We've all heard about “near-death experiences,” which can occur when doctors bring a person back to life after the heart flatlines and breathing stops. Ed examines a new study that may have a scientific and medical explanation of sorts.

Ed delves in a recent study that shows that Attention Deficit Hyperactivity Disorder is associated with a higher incidence of depression, anorexia, or post-traumatic stress disorder, as well as the risk of suicide attempts.

Ed covers a recent study that found that handing your baby a phone or tablet to play with may seem like a harmless solution when you’re busy, but it could quickly affect their development.

Ed explores an in-depth survey that shows that it’s a myth that women lose interest in sex as they enter midlife and beyond.

Ed explains 8 reasons you may feel unrested through the morning or even most of the day even after sleeping for seven to eight hours almost every night.

Ed looks into why alcohol-related deaths are rising for women, and how the issue can be addressed.

Ed delves into the findings of a new study that Artificial intelligence found more breast cancers than doctors with years of training and experience and cut doctors’ mammogram reading workload almost in half.

Ed's recent struggle with insomnia led him to seek ways to quiet his mind so he could get the rest he needed, and shares them with his audience.

Ed examines several treatments that are available for those that experience excessive swampiness.

Ed makes note of the habits this important study found of “SuperAgers” that, whether you're 25 or 65, may help protect your from dementia.

Ed examines how the climate crisis is stacking the deck in favor of more intense weather events across the globe.

The US Food and Drug Administration is expected to decide whether to grant traditional approval to the Alzheimer’s drug Leqembi, the first medicine proven to slow the course of the memory-robbing disease. An approval decision would also be expected to trigger a change in how the Centers for Medicare and Medicaid Services covers the drug, broadening access for up to an estimated million people with...